Project Grant R01AI189899
Award Date
6/2/25
Completion Date
5/31/30
Dollars Obligated
$813K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New Jersey, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $176,152 to Rutgers, The State University of New Jersey to study host-pathogen interactions and carbon processing in glycerol kinase deficient Mycobacterium tuberculosis. The goal is to identify new drug targets to improve the efficacy of tuberculosis (TB) treatment, as drug-tolerant TB strains are a major challenge....
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $265,650 to support research into developing novel medicinal chemistry strategies to overcome drug-resistant tuberculosis (TB). The research aims to (i) establish the structure-activity relationship and mechanism of action of modified rifabutin (RFB) analogs that have shown enhanced potency against...
This federal Project Grant award of $787,171 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel 1,2,4-triazole and pyrrolidine compounds as potential treatments for tuberculosis (TB). The primary objectives are to demonstrate preclinical proof-of-concept for these compound classes, optimize their pharmacological properties, and investigate their unique mechanism of action compared...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $302,421 to Progenra Inc. to evaluate Parkin activators as potential treatments for tuberculosis (TB), including drug-resistant forms of the disease. The research aims to investigate the antimycobacterial efficacy of these small molecule compounds in cellular and animal models of TB, as well as study their mechanism of...
This federal Project Grant award of $1,635,882 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research into developing pro-apoptotic drug treatments for pulmonary tuberculosis (TB). The research aims to leverage cutting-edge imaging technologies and immunophenotyping approaches to gain mechanistic insights on how pro-apoptotic drugs can be used as host-directed therapies to shorten TB...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,350,312 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Los Angeles (UCLA) to develop a rapid phenotypic drug susceptibility testing system for tuberculosis (TB). The project aims to create and optimize novel fluorescent trehalose probes that can detect live Mycobacterium tuberculosis and assess drug resistance, addressing critical limitations...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $817,405.00 to Colorado State University and its subrecipient, the University of Tennessee Health Science Center, to develop new drug regimens for treating tuberculosis (TB), including both drug-sensitive and multidrug-resistant strains. The key objectives are to: 1) manufacture and characterize inhalable dry...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding research to develop novel host-directed therapies (HDTs) using pro-apoptotic drugs as an adjunct treatment for pulmonary tuberculosis (TB). The $774,881 award will support the development of HDT approaches to shorten TB treatments, prevent post-TB lung disease, and improve antibiotic penetration into TB lesions. The...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $749,414 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University for research on the role of macrophage drug efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis. The primary objectives are to: 1) define the role of MDR1 in M.TB survival in macrophages; 2) determine if HSF1 activation or MDR1 inhibition can shorten M.TB sterilization by TB drugs;...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), seeks to optimize novel inhibitors of mycolic acid synthesis as TB drug candidates. The $237,288 award to the University of Central Florida will focus on hit-to-lead optimization and elucidation of structure-activity relationships, using whole cell potency and ADME/PK properties to drive compound prioritization....